Navigation Links
Molecular Detection Inc. Further Strengthens Patent Portfolio Broadly Covering Detection of Antibiotic-Resistant Bacteria
Date:2/7/2013

ng panel with an unmatched combination of accuracy, speed, flexibility and cost-effectiveness.

About Molecular Detection
Molecular Detection Inc. (MDI), a US-based company with offices in Wayne, PA, Tunbridge Wells, UK and Jerusalem, Israel, is developing and commercializing a portfolio of sample-to-answer Detect-Ready® molecular diagnostic tests for the detection of infectious diseases.  The company's first product, a ready-to-use, rapid detection panel for hospital-based MRSA screening, is currently commercially available in the EU and Australia.  MRSA infections represent a growing problem to the healthcare system, and successful MRSA control efforts include the screening of individuals who may be potential carriers to prevent the spread of the disease.  The Detect-Ready MRSA Panel provides increased accuracy, faster time to results and more efficient utilization of hospital resources compared to other MRSA diagnostic products.  MDI's real-time PCR tests are based on novel, patented technologies for differential diagnosis and room-temperature stabilization.  For more information, visit www.detect-ready.com.Contacts: Molecular Detection Inc.:

Media: Todd Wallach

Barbara Lindheim Chief Executive Officer

BLL Partners (215) 896-7001

(212) 584-2276
'/>"/>

SOURCE Molecular Detection Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. A nano car with molecular 4-wheel drive
2. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
3. Chemists become molecular sculptors, synthesizing tiny, molecular traps
4. Why Medicare Carrier Proposes Major Changes in the Handling of Code Stacked Molecular Test Claims is Topic of December 20 Audio Conference
5. Amsterdam Molecular Therapeutics Announces Negative Equity Position
6. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
7. The art of molecular carpet-weaving
8. Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
9. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
10. Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
11. Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 In recent ... motives and methods in product development and promotion has ... industry. This mistrust, fueled by concerns about the insidious ... by reports of spectacular fines to the world’s biggest ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... , , , BRISBANE, ... results from operations for the second quarter and six months ended June 30, ... of 2009 of $36.7 million, or $0.81 per share, compared with a net ... 2008. , , Dan Welch, Chairman, Chief Executive ...
... ... Improved Website. The New Site Provides Users With A Comprehensive Overview Of Pace Analytical ... Also Offers An Expanded Service Description For Each Of Its Three Major Business Divisions: ... ...
... , REDWOOD CITY, Calif., Aug. ... antibody therapeutics that target cancer stem cells, today announced the ... potent anti-cancer activity in colon and breast cancer models for ... of targeting cancer stem cells to treat solid tumors. ...
Cached Biology Technology:InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 2InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 3InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 4InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 5InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 6InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 7InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 8InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 9InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 10InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 11InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 12InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 14InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 15One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions 2Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody 2Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody 3Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody 4
(Date:4/24/2014)... very pleased to announce that it has assumed ownership ... the University of Wisconsin. , The Journal ... peer-reviewed journal that publishes papers on all aspects of ... the molecular to the ecological -- as well as ... to individuals and institutions, and it provides a reasonably ...
(Date:4/24/2014)... by fungus could now be treated in three days, rather ... scientists. , Cryptococcus a form of yeast ... medical research. They are found in many parts of ... mainly affect people with weakened immune systems. This infection kills ... team has tested the effects of the most commonly used ...
(Date:4/24/2014)... Carolina State University and the University of North Carolina ... that could help identify arterial plaque that is at ... or stroke. , At issue is the plaque that ... of plaque are deemed "vulnerable," meaning that they are ... cause heart attack or stroke. , "Existing state-of-the-art technologies ...
Breaking Biology News(10 mins):ESA to publish the Journal of Insect Science 2Treatment for deadly yeast disease reduced to 3 days 2New ultrasound device may add in detecting risk for heart attack, stroke 2
... A team of researchers at the University of ... boardroom in an effort to build a business based ... The work of Claus Tittiger, professor of ... a highly competitive and intense National Science Foundation business-validation ...
... years of research at the Institute of Food Research, ... by food and drug companies worldwide. , IFR and ... secured funding from the Biotechnology and Biological Sciences Research ... to validate and improve how well it simulates the ...
... Pompeu Fabra University (Spain) have created a high resolution atlas ... The study demonstrates that an average image of an organ ... of comparing individual cases and differentiating healthy forms from pathologies. ... heart and its components such as the ventricles and ...
Cached Biology News:Insect research heads down path to start-up company with NSF I-Corps program 2Insect research heads down path to start-up company with NSF I-Corps program 3Commercial future for Model Gut 2An atlas of the human heart is drawn using statistics 2
... polypeptide hormones which belong to the ... TGF- superfamily is a large group ... many aspects of development, reproductive function ... incude TGF-s, bone morphogenetic proteins, growth ...
... EZ-Spread Plating Beads Sterile plating ... for glass rods and potentially hazardous ethanol flaming, ... Two choices of ready-to-use sterile packaging: dispenser bottle ... 50 plating, Fastest and easiest way ...
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... in a regulated environment, Pipette Tracker ... software that automates gravimetric pipette calibration ... that meets todays regulatory compliance requirements. ... solution that includes a full security ...
Biology Products: